![What can we expect from the binding characteristics of azilsartan, a newly available angiotensin II blocker, in hypertension? | Hypertension Research What can we expect from the binding characteristics of azilsartan, a newly available angiotensin II blocker, in hypertension? | Hypertension Research](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fhr.2012.166/MediaObjects/41440_2013_Article_BFhr2012166_Fig1_HTML.jpg)
What can we expect from the binding characteristics of azilsartan, a newly available angiotensin II blocker, in hypertension? | Hypertension Research
![Sartan (irbesartan and losartan) related cluster. In total, 5 urine... | Download Scientific Diagram Sartan (irbesartan and losartan) related cluster. In total, 5 urine... | Download Scientific Diagram](https://www.researchgate.net/profile/Justin-J-J-Hooft/publication/304797106/figure/fig5/AS:380456743784448@1467719364160/Sartan-irbesartan-and-losartan-related-cluster-In-total-5-urine-extracts-contain-1-or.png)
Sartan (irbesartan and losartan) related cluster. In total, 5 urine... | Download Scientific Diagram
![Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells - ScienceDirect Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0223523420302257-fx1.jpg)
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells - ScienceDirect
![Experimental and DFT characterization, antioxidant and anticancer activities of a Cu(II)–irbesartan complex: structure–antihypertensive activity relationships in Cu(II)–sartan complexes | SpringerLink Experimental and DFT characterization, antioxidant and anticancer activities of a Cu(II)–irbesartan complex: structure–antihypertensive activity relationships in Cu(II)–sartan complexes | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00775-016-1384-5/MediaObjects/775_2016_1384_Figa_HTML.gif)
Experimental and DFT characterization, antioxidant and anticancer activities of a Cu(II)–irbesartan complex: structure–antihypertensive activity relationships in Cu(II)–sartan complexes | SpringerLink
![Protein Kinase C-Inhibiting Properties of the Losartan Metabolite EXP3179 Make the Difference | Hypertension Protein Kinase C-Inhibiting Properties of the Losartan Metabolite EXP3179 Make the Difference | Hypertension](https://www.ahajournals.org/cms/asset/4d3788a9-1837-494b-ba22-69221c9476b8/9ff1.jpeg)
Protein Kinase C-Inhibiting Properties of the Losartan Metabolite EXP3179 Make the Difference | Hypertension
Angiotensin II Receptor Blockers (ARBs): Indications, Side Effects, Mechanism of Action, Examples — EZmed
![Antihypertensives This study material is recommended specifically for practical courses from Pharmacology II for students of general medicine and stomatology. - ppt download Antihypertensives This study material is recommended specifically for practical courses from Pharmacology II for students of general medicine and stomatology. - ppt download](https://images.slideplayer.com/31/9746040/slides/slide_15.jpg)
Antihypertensives This study material is recommended specifically for practical courses from Pharmacology II for students of general medicine and stomatology. - ppt download
Study on the coupling relationship between urban resilience and urbanization quality—A case study of 14 cities of Liaoning Province in China
Angiotensin II Receptor Blockers (ARBs): Indications, Side Effects, Mechanism of Action, Examples — EZmed
![Fiche pratique - Médicaments ciblant le système rénine angiotensine - 2. Mode d'action - Propriétés pharmacologiques Fiche pratique - Médicaments ciblant le système rénine angiotensine - 2. Mode d'action - Propriétés pharmacologiques](http://unt-ori2.crihan.fr/unspf/2011_Angers_Faure_Angiotensine/res/SRA.png)